Stephens Inc Gilead Sciences, Inc. Transaction History

Stephens Inc

$6.2 Billion
Q1 2024

A detailed history of Stephens Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Stephens Inc holds 36,447 shares of GILD stock, worth $2.43 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

36,447

Previous 117,686 69.03%

Holding current value

$2.43 Million

Previous $9.53 Million 72.0%

% of portfolio

0.04%

Previous 0.17%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $5.82 Million - $7.09 Million	-81,239 Reduced 69.03%	36,447 $2.67 Million
Q4 2023 Feb 13, 2024	BUY	$73.27 - $83.09 $1.44 Million - $1.63 Million	19,601 Added 19.98%	117,686 $9.53 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $7,615 - $8,309	-103 Reduced 0.1%	98,085 $7.35 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $1 Million - $1.14 Million	-13,173 Reduced 11.83%	98,188 $7.57 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $243,139 - $277,011	3,145 Added 2.91%	111,361 $9.24 Million

Q4 2022 Jan 25, 2023	BUY	$62.32 - $89.47 $2.67 Million - $3.84 Million	42,869 Added 65.6%	108,216 $9.29 Million
Q3 2022 Nov 02, 2022	SELL	$59.54 - $68.01 $142,955 - $163,292	-2,401 Reduced 3.54%	65,347 $4.03 Million
Q2 2022 Aug 03, 2022	BUY	$57.72 - $65.01 $22,683 - $25,548	393 Added 0.58%	67,748 $4.19 Million
Q1 2022 May 04, 2022	SELL	$57.92 - $72.58 $510,043 - $639,139	-8,806 Reduced 11.56%	67,355 $4 Million
Q4 2021 Mar 07, 2022	SELL	$64.88 - $73.64 $2.48 Million - $2.81 Million	-38,204 Reduced 33.41%	76,161 $5.53 Million
Q3 2021 Oct 27, 2021	BUY	$67.69 - $73.03 $237,321 - $256,043	3,506 Added 3.16%	114,365 $7.99 Million
Q2 2021 Aug 12, 2021	BUY	$63.47 - $69.35 $343,690 - $375,530	5,415 Added 5.14%	110,859 $7.63 Million
Q1 2021 May 14, 2021	BUY	$60.0 - $68.46 $597,180 - $681,382	9,953 Added 10.42%	105,444 $6.82 Million
Q4 2020 Feb 10, 2021	SELL	$56.65 - $64.55 $1.01 Million - $1.15 Million	-17,796 Reduced 15.71%	95,491 $5.56 Million
Q3 2020 Nov 13, 2020	BUY	$62.1 - $78.08 $2.1 Million - $2.64 Million	33,797 Added 42.52%	113,287 $7.16 Million
Q2 2020 Aug 24, 2020	SELL	$72.34 - $84.0 $4.06 Million - $4.72 Million	-56,147 Reduced 41.4%	79,490 $6.12 Million
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $953,980 - $1.22 Million	-15,232 Reduced 10.1%	135,637 $10.1 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $1.29 Million - $1.42 Million	-20,946 Reduced 12.19%	150,869 $9.8 Million
Q3 2019 Oct 18, 2019	BUY	$62.51 - $69.0 $5.17 Million - $5.7 Million	82,675 Added 92.75%	171,815 $10.9 Million
Q2 2019 Aug 01, 2019	BUY	$61.87 - $69.38 $1.68 Million - $1.88 Million	27,162 Added 43.83%	89,140 $6.02 Million
Q1 2019 May 03, 2019	BUY	$62.53 - $70.05 $481,168 - $539,034	7,695 Added 14.18%	61,978 $4.03 Million
Q4 2018 Feb 11, 2019	SELL	$60.54 - $79.0 $174,113 - $227,204	-2,876 Reduced 5.03%	54,283 $3.4 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $61,158 - $67,713	-858 Reduced 1.48%	57,159 $4.41 Million
Q2 2018 Aug 10, 2018	SELL	$64.88 - $75.68 $197,429 - $230,294	-3,043 Reduced 4.98%	58,017 $4.11 Million
Q1 2018 May 03, 2018	BUY	$72.84 - $88.8 $109,697 - $133,732	1,506 Added 2.53%	61,060 $4.6 Million
Q4 2017 Feb 05, 2018	SELL	$71.15 - $83.52 $726,726 - $853,073	-10,214 Reduced 14.64%	59,554 $4.27 Million
Q3 2017 Nov 08, 2017	BUY	$72.11 - $85.47 $72,037 - $85,384	999 Added 1.45%	69,768 $5.65 Million
Q2 2017 Aug 10, 2017	BUY	N/A	68,769	68,769 $4.87 Million

Others Institutions Holding GILD

# of Institutions

1,885

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $83.5B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

News

Stay updated on Stephens Inc with notifications on news.

Account